Workshop CE Evaluations Logo

  • Workshop CE Evaluations

    Psychedelic Science 2025

  • Instructions

  • Use this form to complete evaluations for each workshop you attended. 

    • Pages are linked in tabs at the top of this page.
    • You can save the form and return to it at any time. When you save the form, you will be prompted to either create an account using your email address or sign up with Google. Alternatively, you can skip creating an account and copy your unique form link. If you create an account, you will receive an email to verify your account and a second email with your form link. Either option will save your progress.
    • Please complete (submit) only one form per person by July 4, 2025.

  • Learner Information

  • Monday, June 16

    • Guiding Psilocybin Therapy Sessions 

    • At the end of the session, the learner will be able to:

      1. Assess 3 areas of proficiency as related to the primary therapeutic competencies for guiding psychedelic sessions.
      2. Explain 3 of the basic principles that appear to expedite the safe and beneficial exploration of consciousness.
      3. Describe 3 ways to integrate a psychedelic experience.
      4. Name 3 reasons why preparatory meetings are important before a psychedelic
      session.
      5. Compare and contrast at least 3 areas of comfort and discomfort that I experienced during the role plays of therapeutic competencies.
      6. Assess my proficiency in the role plays regarding 2-3 primary therapeutic competencies for guiding psychedelic sessions: presence, empathy, care, and authenticity.

    • Introduction to Psychedelic Neuroscience 

    • At the end of the session, the learner will be able to:

      1. Describe the putative neural mechanisms underlying psychedelic-induced therapeutic change.
      2. Discuss the empirical findings linking psychedelic brain effects and therapeutic outcomes in humans.
      3. Explain the integrative biopsychosocial models of psychedelic effects.
      4. Describe how neuron activity during psychedelic exposure may or may not be related to long-term plasticity.

    • MDMA-Assisted Therapy for PTSD: Observations from 20 Years of Clinical Research 

    • At the end of the session, the learner will be able to:

      1. Describe the history, chemical structure, and rationale for researching MDMA-assisted therapy for PTSD.
      2. List 5 of the neurophysiological effects of MDMA.
      3. Discuss the design and results of Phase 2 and Phase 3 clinical trials.
      4. Discuss the challenges to studying pharmacology in conjunction with psychotherapy.

    • Unlocking the Self: Integrating Internal Family Systems with Psychedelic Therapy 

    • At the end of the session, the learner will be able to:

      1. Discuss the integration of Internal Family Systems (IFS) therapy with Psychedelic-Assisted Psychotherapy.
      2. Explain how unburdening internal parts can facilitate access to the 8 Cs of Self.
      3. Describe psycholytic and mid-dose ketamine approaches in therapy.
      4. Identify insights into preparing for psychedelic journeys by obtaining consent from protectors and ensuring effective integration processes.
      5. Discuss strategies for utilizing IFS principles to support healing and transformation during psychedelic experiences.

    • Diversity & Cultural Competency in Psychedelic-Assisted Therapy 

    • At the end of the session, the learner will be able to:

      1. Identify barriers to psychedelic-assisted therapy for minoritized racial and ethnic groups.
      2. Explain the importance of empathy in being an effective clinician for people with marginalized identities.
      3. Describe the harm of microaggressions during psychedelic therapy.
      4. Describe key methods for effective outreach and retention of diverse clients.

    • MDMA-Assisted Couples Therapy 

    • At the end of the session, the learner will be able to:

      1. Describe the therapeutic components of MDMA-assisted couples therapy.
      2. Compare and contrast the use of MDMA-assisted couples therapy for the treatment of PTSD and for general relationship functioning.
      3. Discuss the design and results of the MDMA-assisted couples therapy trial.

  • Tuesday, June 17th

    • Psilocybin as a Tool in Personal and Spiritual Development 

    • At the end of the session, the learner will be able to:

      1. Explain an overview of the gold standard of care for experiential medicine in health care systems.
      2. Describe patient safety and risk management strategies.
      3. Discuss how advanced screening techniques are applied in clinical trials.

    • Introduction to Psychedelic Therapy for the Treatment of Addiction 

    • At the end of the session, the learner will be able to:

      1. Identify the limitations of current behavioral and pharmacological treatments for substance use disorders and the public health implications of rising addiction rates.
      2. Describe the historical context and current state of research on psychedelic-assisted therapies for addiction, including studies involving substances such as psilocybin, MDMA, and ibogaine.
      3. Evaluate emerging clinical protocols and therapeutic approaches in psychedelic-assisted treatment for various substance use disorders, with attention to safety, efficacy, and integration into existing care models.

    • Psychedelic Therapy for End-of-Life and Palliative Care 

    • At the end of the session, the learner will be able to:

      1. Describe demoralization syndrome, observed in patients with a life-threatening illness or near the end of life.
      2. Discuss the scientific findings from psilocybin trials treating cancer-associated distress, notably findings regarding depression, anxiety, hopelessness, and demoralization.
      3. Explain the set and setting and the phases of the psychedelic treatment model - preparation, medication, and integration sessions.
      4. Describe the primary features of a psychedelic-generated mystical experience (shown to be correlated with enhanced outcomes in some psychedelic therapy trials with cancer patients).

    • Applying MDMA-Assisted Therapy Principles in Current Clinical and Research Settings 

    • At the end of the session, the learner will be able to:

      1. Describe the importance of pairing practitioners with participants/clients in terms of social location,
      identity, and capacity for intensity.
      2. Identify core aspects of the change process in psychedelic-assisted therapy.
      3. List signs, symbols, or patterns of change in participants in psychedelic-assisted therapy.
      4. Describe an example of when destabilization is unhealthy for participants/clients.

    • Self- and Sensory Experience in Psychedelic Therapies: Exploring Growth Edges with Expanded Awareness in Psychedelics 

    • At the end of the session, the learner will be able to:

      1. Describe how trauma impacts self-perception, emotional regulation, and sensory experience, and how psychedelic-assisted therapy may help restore a sense of vitality, awareness, and self-compassion.
      2. Summarize key findings from MAPS-sponsored MDMA-assisted therapy studies for chronic PTSD, including improvements in alexithymia, self-regulation, and interpersonal understanding.
      3. Explain the importance of preparation, intention-setting, attunement, and integration in maximizing the therapeutic benefits of psychedelic experiences, and the therapist’s role in supporting an inner-directed healing process.

    • Psychedelic Chemistry: Foundations for Innovation 

    • At the end of the session, the learner will be able to:

      1. Explain key chemical principles—such as acid-base behavior and molecular structure—that influence the properties, formulation, and physiological activity of psychedelic compounds.
      2. Describe how structure-activity relationships, synthetic strategies, and analytical techniques inform the development and scaling of psychedelic substances for research and therapeutic use.
      3. Discuss advances in synthetic methods and other innovative approaches to creating and characterizing psychedelic compounds.

    • Ibogaine Treatment: Therapeutic Targets, Efficacy, Subjective Effects, and Post-treatment Integration 

    • At the end of the session, the learner will be able to:


      1. Identify the reasons why and conditions for which people seek ibogaine-assisted treatment and distinguish between those conditions for which ibogaine has been proven effective and those for which there is not yet any scientific literature proving ibogaine’s efficacy in treatment.
      2. Discuss the known risk factors for people undergoing ibogaine treatment and recall specific treatment contraindications and strategies for treatment risk mitigation.
      3. Describe the core components of effective preparation for an ibogaine journey, identify the essential elements of pre-treatment preparation, and apply evidence-based integration strategies for patients following an ibogaine journey.

    • Should be Empty: